跳至主要内容
临床试验/NCT05813483
NCT05813483尚未招募不适用

A Prospective, Single-Center, Single-Blind, Randomized Split-Face Controlled Clinical Study to Evaluate the Efficacy and Satisfaction of the Skinceuticals Skin Care Product (CE) for Skin Repair Post Fraxel Laser Treatment in Real World Clinical Practice

DeYi Aesthetic Medical Clinic0 个研究点目标入组 50 人开始时间: 2023年4月17日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
主要终点
Change in erythema score

研究概览

简要总结

A Prospective, Single-center, Single-blind, Randomized split-face, controlled trial will be conducted. The goal of this clinical trial is to evaluate the efficacy and satisfaction of the Skinceuticals skin care product (CE) for skin repair following fraxel laser treatment and explore the medical value of fraxel laser therapy combined with Skinceuticals skin care product

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chinese subjects aged 18-65 years (inclusive);
  • Subjects with Fitzpatrick skin type II-IV;
  • Subjects with consistent facial skin status on both sides and planned to receive fraxel laser treatment;
  • Subjects are willing to follow the requirements of the study protocol and complete the corresponding procedures;
  • Subjects understand the nature of the study and sign the informed consent form (ICF).

排除标准

  • Subjects with photosensitive skin or photosensitization-related diseases;
  • Subjects with a history of skin pigmentation, such as pigmentation caused by sex hormone factors (pregnancy, oral contraceptives);
  • Subjects with hypertrophic scar or scar constitution;
  • Subjects with autoimmune diseases, endocrine diseases or liver diseases that may lead to skin color changes;
  • Subjects who have received steroid/phototoxic drugs or laser treatment on the face within 3 months before enrollment;
  • Subjects with a history of sun exposure within 2 weeks prior to enrollment;
  • Subjects who are known to be contraindicated to fraxel laser therapy or CE (or allergic to other skin care components);
  • Subjects with known infection and inflammation in the intended treatment site;
  • Female subjects who are pregnant, lactating or plan to become pregnant;
  • Subjects who plan to use other drugs affecting skin color or intend to undergo other laser therapy and sunbathing during the treatment;
  • Subjects who are participating in other drug or medical device clinical trials;
  • Other subjects who are not suitable for this study as assessed by the investigator

结局指标

主要结局

Change in erythema score

时间窗: at day 7 post-procedure

Scoring criteria: 0 (no erythema), 1 (mild erythema), 2 (moderate erythema), and 3 (severe erythema)

次要结局

  • Change from baseline in erythema score(days 1, 3, 5 post-procedure)
  • Change from baseline in edema score(days 1, 3, 5 ,7 post-procedure)
  • Change from baseline in Erythema Index (EI)(days 1, 3, 5 ,7 post-procedure)
  • Change from baseline in melanin index(MI) Change from baseline in melanin index(MI)(days 1, 3, 5 ,7 post-procedure)
  • Change from baseline in stratum corneum water content(days 1, 3, 5 ,7 post-procedure)
  • Change from baseline in transepidermal water loss(days 1, 3, 5 ,7 post-procedure)
  • Change from baseline in sebum rate(days 1, 3, 5 ,7 post-procedure)
  • Subjects overall satisfaction(days 1, 3, 5 ,7 post-procedure)

研究者

发起方
DeYi Aesthetic Medical Clinic
申办方类型
Other
责任方
Sponsor

相似试验